Ontology highlight
ABSTRACT:
SUBMITTER: Wagner J
PROVIDER: S-EPMC5983321 | biostudies-literature | 2018 Jun
REPOSITORIES: biostudies-literature
Wagner Jessica J Kline C Leah CL Zhou Lanlan L Campbell Kerry S KS MacFarlane Alexander W AW Olszanski Anthony J AJ Cai Kathy Q KQ Hensley Harvey H HH Ross Eric A EA Ralff Marie D MD Zloza Andrew A Chesson Charles B CB Newman Jenna H JH Kaufman Howard H Bertino Joseph J Stein Mark M El-Deiry Wafik S WS
The Journal of clinical investigation 20180430 6
ONC201 is a first-in-class, orally active antitumor agent that upregulates cytotoxic TRAIL pathway signaling in cancer cells. ONC201 has demonstrated safety and preliminary efficacy in a first-in-human trial in which patients were dosed every 3 weeks. We hypothesized that dose intensification of ONC201 may impact antitumor efficacy. We discovered that ONC201 exerts dose- and schedule-dependent effects on tumor progression and cell death signaling in vivo. With dose intensification, we note a pot ...[more]